The airways of people with cystic fibrosis (CF) are chronically colonised with different pathogens. With recent interest in methicillin-resistant Staphylococcusaureus (MRSA), we have recently examined the rates of MRSA colonisation in different groups within our CF Service. This paper now examines the effectiveness of eradication strategies to clear the MRSA colonisation.
6 April 2025 in Transplantation and Cellular Therapy
Pulmonary graft versus host disease is a common and serious complication of haematopoietic stem cell transplant (HSCT). Early diagnosis is essential for rapid treatment before irreversible changes in lung function occur. The NIH support that a decline in forced expiratory volume in 1 second (FEV1) of ≥10% from baseline values require further investigation and close monitoring post HSCT-transplant. Previous research demonstrates that a 10-19% and ≥20% reduction in FEV1, within 6 months of transplant, is associated with higher odds of 1-mortality; however, to the authors' knowledge, there is no long-term follow-up data of FEV1 decline with an onset after the first 6-month period. We aimed to investigate the clinical significance of a ≥10% decrement in FEV1 measured by spirometry for predicting all-cause mortality in HSCT recipients, over a period of 5-years. A comparison was made to patients who met the NIH diagnostic criteria for lung GvHD. Long-term follow-up data of patients who received an allogeneic HSCT at Westmead was retrospectively audited, using a censoring period of 5-years. A decrease in lung function was defined as a change in FEV1 by ≥10% from their best value, usually at the beginning of the transplant process. Recovery was defined as a ≥10% increase in FEV1, from the patient's maximum decline in lung function. A diagnosis of lung GvHD was made when the following criteria were met: FEV1/FVC ratio of < 0.7, and an FEV1 <75% of predicted normal with ≥10% reduction over less than two years and evidence of gas trapping. Data from 364 patients who underwent an allogeneic HSCT between 2013 and 2019 were analysed; 173 patients (47.7%) experienced a ≥10% reduction in FEV1 after transplant. Ninety-five patients experienced an FEV1 decline lasting 6 months and were unlikely to recover any lost lung function (median % FEV recovered = 0%). There was a significant relationship between ≥10% FEV1 decline and death, X2(1, 364) = 15.67, p <0.001. All-cause mortality was doubled in those who experienced ≥10% FEV1 decline (34%), compared with those without any decline (16%). Mortality was highest in those who experienced decline without any recovery (OR = 2.98 [1.64-5.41]). However, in the group who had a decline and then later recovered mortality was still elevated (OR = 2.08 [1.17-3.69]) compared with those who did not experience any FEV1 decline ≥10%. Mortality risk is elevated from the first ≥10% reduction in FEV1 and remains elevated even if FEV1 recovery occurs. Individuals whose FEV1 declines for longer than 6 months are unlikely to experience FEV1 recovery, despite treatment. An FEV1 decline of at least ≥10% from pre-transplant value should trigger rapid assessment to identify and treat mortality risks, and to minimise decline in overall respiratory function.
Cystic Fibrosis (CF), the most common lethal inherited disorder in Australia, is associated with increased respiratory tract colonization/infection. Given that many adults with CF work as health‐care workers (HCW), which has been associated with an increased risk of methicillin‐resistant Staphylococcus aureus (MRSA) colonization/infection, we examined these risks in 252 adults with CF at our centre between 2001–2015. Demographic and clinical characteristics, including pathogens, were compared for HCW and non‐HCW groups. MRSA colonization/infection was found in 20 subjects, comprising 2/19 HCW, and 18/233 non‐HCW (p = 0.66). Sixteen of these 20 subjects undertook eradication therapy, with success in 2/2 HCW and 5/14 non‐HCW. This study showed that the rate of MRSA colonization/infection did not differ between adults with CF who work in the health‐care setting versus other areas. This suggests that choosing a health‐care profession does not necessarily result in an increased risk of MRSA colonization/infection for an adult with CF.
Introduction Colonoscopy plays important roles in bowel cancer screening and treatment. Poor bowel preparation occurs in 20–25% of colonoscopies. This negatively impacts adenoma and sessile serrated lesion detection rates, procedural time, requirement for repeat colonoscopies, healthcare costs and likelihood of patient withdrawal from screening programmes. It is unclear whether a combination of multimedia modalities can improve bowel preparation quality, adenoma detection rates and patient-reported measures in those undergoing colonoscopy assessment. Methods The DIGICLEAN trial is a prospective, parallel, multicentre, colonoscopist-blinded, randomised controlled trial. The trial will enrol 1294 participants aged 45 years and older who are indicated for a colonoscopy as an outpatient with a positive faecal occult blood test, iron deficiency anaemia or rectal bleeding. Participants will be randomised into the interventional arm, where bowel preparation instructions are delivered via a web-based application which uses scheduled short messaging service, regular patient survey assessment, email and videos; or the control arm, where routine standard written, verbal or emailed instructions are administered. The web-based application will assess patient-reported bloating, constipation and dietary adherence leading up to the colonoscopy. Depending on patient responses, additional aperients may be encouraged digitally in the interventional arm with same instructions made available in written format for the control arm. Patient-reported measures will be collected in both arms the day after the procedure using the validated Newcastle ENDOPREM questionnaire. In some sites, participants will undergo digital pre-anaesthetic screening as well. The co-primary endpoints are the adenoma detection rates and patient-reported measures taken after the colonoscopy. Ethics and dissemination Ethics approval for this study was obtained from the Western Sydney Local Health District Human Research Ethics Committee (2022/ETH00059). Findings will be reported at national and international gastroenterology meetings and published in peer-reviewed journals. Trial registration number ACTRN12622000747729.